ProCervix: Additional Phase II data

Additional data from 233 evaluable patients ages 25-50 infected with HPV types 16 and/or 18 in the

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE